Villanova Investment Management Co LLC Sells 33,760 Shares of DENTSPLY SIRONA Inc. $XRAY

Key Points

• Villanova Investment Management Co LLC significantly reduced its holdings in DENTSPLY SIRONA, selling 33,760 shares and decreasing its position by 54.6% in the first quarter.
• Several analysts have adjusted their ratings for DENTSPLY SIRONA, with two giving a Buy rating and eleven maintaining a Hold rating, amidst target price changes.
• DENTSPLY SIRONA reported earnings of $0.52 per share, outperforming estimates, despite a 4.9% revenue decline year-over-year.

Villanova Investment Management Co LLC reduced its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 54.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,040 shares of the medical instruments supplier's stock after selling 33,760 shares during the quarter. Villanova Investment Management Co LLC's holdings in DENTSPLY SIRONA were worth $419,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Gabelli Funds LLC raised its holdings in DENTSPLY SIRONA by 1.0% in the first quarter. Gabelli Funds LLC now owns 98,000 shares of the medical instruments supplier's stock worth $1,464,000 after purchasing an additional 1,000 shares in the last quarter. Empowered Funds LLC boosted its position in DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier's stock valued at $244,000 after buying an additional 1,320 shares during the last quarter. Covestor Ltd boosted its position in DENTSPLY SIRONA by 17.5% in the first quarter. Covestor Ltd now owns 9,778 shares of the medical instruments supplier's stock valued at $146,000 after buying an additional 1,456 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in DENTSPLY SIRONA in the 1st quarter worth approximately $25,000. Finally, Principal Financial Group Inc. boosted its position in DENTSPLY SIRONA by 0.4% in the 1st quarter. Principal Financial Group Inc. now owns 457,397 shares of the medical instruments supplier's stock worth $6,834,000 after purchasing an additional 1,708 shares in the last quarter. 95.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on XRAY. Wall Street Zen downgraded shares of DENTSPLY SIRONA from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. UBS Group cut their target price on DENTSPLY SIRONA from $25.00 to $24.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Needham & Company LLC reissued a "hold" rating on shares of DENTSPLY SIRONA in a research report on Monday, July 21st. Stifel Nicolaus cut their price objective on shares of DENTSPLY SIRONA from $19.00 to $17.00 and set a "hold" rating for the company in a research report on Friday, August 8th. Finally, Barrington Research decreased their target price on shares of DENTSPLY SIRONA from $21.00 to $18.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $18.64.

DENTSPLY SIRONA Stock Down 1.5%

Shares of NASDAQ XRAY opened at $13.70 on Thursday. DENTSPLY SIRONA Inc. has a 52-week low of $12.16 and a 52-week high of $27.48. The business's 50 day moving average is $14.85 and its two-hundred day moving average is $15.12. The firm has a market cap of $2.73 billion, a price-to-earnings ratio of -2.89, a PEG ratio of 0.87 and a beta of 0.96. The company has a quick ratio of 1.11, a current ratio of 1.69 and a debt-to-equity ratio of 1.13.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.02. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%.The firm had revenue of $936.00 million for the quarter, compared to analyst estimates of $929.67 million. During the same quarter in the prior year, the company earned $0.49 EPS. DENTSPLY SIRONA's revenue was down 4.9% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2025 guidance at 1.800-2.000 EPS. Research analysts predict that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current year.

DENTSPLY SIRONA Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 10th. Stockholders of record on Friday, September 26th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $0.64 annualized dividend and a dividend yield of 4.7%. DENTSPLY SIRONA's dividend payout ratio (DPR) is presently -13.50%.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.